Abstract
This study evaluated the real-world outcomes among patients (pts) with squamous (SQ) or non-squamous cell (NSQ) advanced non-small cell lung cancer (aNSCLC) receiving either first-line (1L) immuno-oncology (IO) monotherapy or IO in combination with chemotherapy (IO+CT).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.